INTRODUCTION
============

Vulvovaginal candidiasis (VVC) is a disease caused by the abnormal growth of yeast-like fungi in the mucosa of the female genital tract by members of the genus *Candida* [@B21]. These yeasts, in particular *C. albicans*, are well adapted to the human body, and are capable of colonizing it without producing signs of disease in conditions of physiological equilibrium[@B28]. However, under conditions that disrupt the delicate balance between the host and this commensal fungus, a parasitic relationship may occur, resulting in the development of infections termed candidiasis, including VVC[@B02]. For development of VVC, predisposing factors related to the host are very important, mainly being immunosuppressive diseases, such as HIV infection[@B13] ^,^ [@B15].

Because it strikes millions of women annually, causing great discomfort, interfering with sexual and affective relations and impairing work performance, VVC has been considered an important worldwide public-health problem[@B05] ^,^ [@B24]. In HIV-infected women, the impact of VVC on top of other medical complications that stem from the viral infection and its treatment certainly contributes to the impairment of their quality of life. It must still be considered that out of HIV-infected individuals worldwide (around 40 million), nearly half are women[@B16], raising concerns about VVC. In Brazil, HIV infection occurs in 0.5% of the population, with a trend toward expansion of the epidemic among women, from a ratio of 18.5 men:1 woman in the 1980s to 1.5:1 in 2004[@B02].

Use of the highly active antiretroviral therapy (HAART) has extended the life span of HIV-infected persons. However, some studies have reported that even for users of this continuous therapy opportunistic infections remain a serious problem[@B03] ^,^ [@B18]. Nevertheless, to the authors\' knowledge, few studies have related vaginal *Candida* colonization and VVC in HIV-infected women to HAART use in different populations, have enrolled relatively few HIV-infected women[@B15], only treated specific clinical conditions as *Candida* colonization[@B14], lacked appropriate matched controls[@B09] ^,^ [@B15], or have been restricted to specialized subpopulations such as women with symptoms of vulvovaginitis[@B23]. There are some available studies that were performed before the broad use of HAART or in populations that do not regularly use this therapy[@B01] ^,^ [@B04] ^,^ [@B09] ^,^ [@B23] ^,^ [@B27].

The aim of this study was to evaluate the effect of HAART use on the vaginal *Candida* spp. isolation in two clinical conditions: colonization and VVC, in HIV-infected compared to HIV-uninfected women. In addition, the antifungal susceptibility of *Candida* species to the most commonly used antifungal drugs was evaluated.

MATERIAL AND METHODS
====================

This was a cross-sectional study that included a group of 178 HIV-infected and 200 HIV-uninfected women, who were studied at the Specialized Assistance Service (SAE) for sexually transmitted diseases (STD)/AIDS in the city of Maringá, Brazil, from April 1 to October 30, 2011. Inclusion criteria were women having diagnoses of HIV/AIDS confirmed by two different methods (HIV group), or confirmed diagnosis as HIV-uninfected (control group). Exclusion criteria were: hysterectomized women, pregnant or postpartum women, women of less than 18 years of age, women with no history of sexual activity, women that had some degree of difficulty in understanding the study, women suffering vaginal bleeding, or women that had undergone sexual intercourse/vaginal douching within the 48 hours preceding collection of the vaginal sample.

The women signed the consent form to participate in the study, and completed a standardized questionnaire with information regarding symptoms of VVC. The HIV group also responded to a questionnaire regarding socio-demographic characteristics, obstetrical and gynecological history, and sexual behavior. Data regarding HIV infection, including the period of infection (years), CD4^+^ T lymphocyte count, HIV viral load values, and HAART use were obtained from the medical records of each woman. A single health professional was responsible for contacting the women, administering the questionnaire, and collecting the vaginal sample. This research was approved by the Committee for Ethics in Research Involving Humans at the State University of Maringá, Paraná, Brazil (reports No. 185/2007 and No. 085/2011).

Vaginal samples were collected with sterile swabs and a disposable vaginal speculum, inoculated in sterile saline, and immediately seeded onto plates containing Sabouraud dextrose agar (SDA) (Difco, USA), with the addition of 100 mg/mL chloramphenicol, and incubated at 25 °C for up to five days. A pool of the colonies grown on each plate was subcultured on CHROMágar *Candida* ^®^ (Probac, France) to assure the purity of the isolates and to identify mixed cultures. Beginning with the pure culture, the yeasts were identified by classical phenotypic methods[@B11]. Additionally, the identification of yeasts was confirmed using matrix-assisted laser-desorption/ionization time-of-flight mass spectroscopy assay (MALDI TOF-MS). For MALDI TOF-MS identification, yeasts were prepared[@B26] and the measurements were performed[@B19] with Microflex LT mass spectrometer (Bruker Daltonics, Germany) using FlexControl software (version 3.0, Bruker Daltonics, Germany). The yeasts were stored in Sabouraud dextrose broth (SDB) (Difco, USA) with 10% glycerol at -20 °C.

Women were evaluated for the presence of clinical signs and symptoms of VVC by SAE doctors. *Candida* vaginal colonization was defined as culture positive for yeasts from women without signs and symptoms of VVC. Women with a positive culture were considered to have VVC if they reported at least two symptoms of this pathology (discharge, burning, vaginal itching, dysuria or dyspareunia), and signs of VVC reported by doctors[@B12].

The *in vitro* antifungal activity assay was performed for fluconazole (FLU, Pfizer Inc. , NY, USA), itraconazole (ITRA, Janssen Pharmaceutical, NJ, USA), nystatin (NYST, Sigma Pharma, MO, USA) and Amphotericin B (AMB, Squibb Pharmaceutical, NJ, USA). All yeasts isolated were tested by means of the Clinical Laboratory Standards Institute reference broth microdilution method for fluconazol and itraconazol, with modifications for other drugs[@B04] ^,^ [@B05]. The minimum inhibitory concentration (MIC) for azoles was defined as the first well with a significant growth reduction (approximately 50%) compared to that of the positive control. In the case of NYST and AMB, the MIC was defined as the lowest concentration capable of inhibiting 90% of the growth[@B17]. The endpoints for antifungal agents: isolates with MIC between 16 and 32 µg/mL for FLU, 0.25 to 0.5 µg/mL for ITRA, and 8 to 32 µg/mL for NYST were considered as dose-dependent susceptibility (DDS). Isolates with an MIC ≤ 8 µg/mL for FLU, ≤ 0.125 µg/mL for ITRA, ≤ 4 µg/mL for NYST, and ≤ 1 µg/mL for AMB were susceptible (S). Those with an MIC ≥ 64 µg/mL for FLU, ≥ 1 µg/mL for ITRA, ≥ 64 µg/mL for NYST and ≥ 2 µg/mL for AMB were resistant (R).

The statistical analysis was performed using the STATA for Statistics and Data Analysis 9.1 software. All variables were expressed as absolute and relative frequencies. The frequencies of *Candida* spp. isolation from the vaginal mucosa, and also colonization and VVC, were calculated by the crude odds ratio (OR) with a 95% confidence interval (CI), and were evaluated between groups by the Chi-square test (χ^2^) with Yates correction. A value of *p* \< 0.05 was considered significant.

RESULTS
=======

[Figure 1](#f01){ref-type="fig"} is an overview of the study and results.

![](0036-4665-rimtsp-57-02-0169-gf01){#f01}

[Table 1](#t01){ref-type="table"} describes the socio-demographic and clinical characteristics of the two groups. The median age of the HIV group was 41.24 ± 10.31 years, and for the control group it was 42.22 ± 14.14 years (*p* \> 0.05). Considering all women studied, *Candida* spp. isolation from the vaginal mucosa and VVC was significantly associated with the 31 to 40 years of age group (*p* = 0.0286 and *p* = 0.0131, respectively). For the groups studied, only the control group showed association with age, since vaginal yeast colonization was significantly associated with the 31 to 40 years of age group (*p* = 0.0185). Data regarding HIV infection, including the period of HIV infection, CD4^+^ T lymphocyte count, HIV viral load values and correct use of HAART were not significantly associated with *Candida* spp. total isolation, colonization or VVC.

###### Relationship between total *Candida* vaginal isolation, colonization and VCC, as well as the socio-demographic characteristics, obstetrical and gynecological history, sexual behavior and data regarding HIV of 178 HIV-infected women

  Characteristics of *Candida* spp. in HIV-infected women   HIV-infected *n* = 178              Positive *Candida* isolation *n* = 36   *p* -value   Colonization *n* = 19   *p* -value                                             VVC *n* = 17   *p* -value                        
  --------------------------------------------------------- ----------------------------------- --------------------------------------- ------------ ----------------------- ------------ ----------------------------------------- -------------- ------------ -------- ---- ------ -----------------------------------------
  **Age (years)**                                                                                                                                                                                                                                                                    
                                                            15 to 30                            28                                      15.7         10                      27.8         0.4206                                    4              21.1         0.7867   6    35.3   0.2861
                                                            31 to 40                            60                                      33.7         17                      47.2         0.0286[\*](#TFN01){ref-type="table-fn"}   7              36.8         0.2285   10   58.8   0.0131[\*](#TFN01){ref-type="table-fn"}
                                                            ≥ 41                                90                                      50.6         9                       25.0         0.1400                                    8              42.1         0.646    1    5.9    0.2103
  **Marital status**                                                                                                                                                                                                                                                                 
                                                            married/cohabiting                  93                                      52.2         19                      52.8         0.9494                                    7              36.8         0.4337   12   70.6   0.2264
                                                            unmarried/non-cohabiting            85                                      47.8         17                      47.2         0.9521                                    12             63.2         0.3204   5    29.4   0.4202
  **Education**                                                                                                                                                                                                                                                                      
                                                            \< 8 years                          85                                      47.8         12                      33.3         0.3414                                    5              26.3         0.3515   7    41.2   0.7375
                                                            ≥ 8 years                           93                                      52.2         24                      66.7         0.1994                                    14             73.7         0.8782   10   58.8   0.6832
  **Family income**                                                                                                                                                                                                                                                                  
                                                            \< \$ 240/month                     25                                      14.0         4                       11.1         0.8763                                    2              10.5         0.8911   2    11.8   0.9316
                                                            ≥ \$ 240/month                      153                                     86.0         32                      88.9         0.6519                                    17             89.5         0.6906   15   88.2   0.8139
  **Skin color**                                                                                                                                                                                                                                                                     
                                                            white                               109                                     61.2         18                      50.0         0.3803                                    11             57.9         0.8311   7    41.2   0.3025
                                                            brown                               50                                      28.1         12                      33.3         0.7177                                    6              31.6         0.8582   6    35.3   0.7105
                                                            black                               15                                      8.4          6                       16.7         0.5635                                    2              10.5         0.9222   4    23.5   0.3957
                                                            yellow                              4                                       2.2          0                       0.0          \-                                        0              0.0          \-       0    0      \-
  **Employ out side the home**                                                                                                                                                                                                                                                       
                                                            yes                                 98                                      55.1         23                      63.9         0.4397                                    13             68.4         0.3652   10   58.9   0.8136
                                                            No                                  80                                      44.9         13                      36.1         0.5500                                    6              31.6         0.5254   7    41.1   0.8467
  **Age of first sexual intercourse**                                                                                                                                                                                                                                                
                                                            \< 18                               112                                     62.9         24                      66.7         0.7329                                    15             78.9         0.2254   9    53.0   0.5527
                                                            ≥ 18                                66                                      37.1         12                      33.3         0.8071                                    4              21.1         0.5201   8    47.0   0.584
  **Number of lifetime sexual partners**                                                                                                                                                                                                                                             
                                                            \< 10                               129                                     72.5         25                      69.4         0.7923                                    14             73.7         0.953    11   64.8   0.6127
                                                            ≥ 10                                49                                      27.5         11                      30.6         0.8635                                    5              26.3         0.9545   6    35.2   0.7146
  **Number of deliveries**                                                                                                                                                                                                                                                           
                                                            \< 3                                87                                      48.9         17                      47.2         0.8922                                    8              42.1         0.7135   9    53.0   0.8198
                                                            ≥ 3                                 91                                      51.1         19                      52.8         \-                                        11             57.9         0.6708   8    47.0   0.8287
  **Period of HIV infection (years)**                                                                                                                                                                                                                                                
                                                            \< 10                               131                                     73.6         25                      69.4         0.6346                                    15             78.9         0.6576   10   58.9   0.3021
                                                            ≥ 10                                47                                      26.4         11                      30.6         0.7579                                    4              21.1         0.8175   7    41.1   0.4101
  **HAART use**                                                                                                                                                                                                                                                                      
                                                            yes                                 141                                     79.2         22                      61.1         0.0670                                    13             68.4         0.3676   9    53.0   0.0724
                                                            no                                  37                                      20.8         14                      38.9         0.1990                                    6              31.6         0.5588   8    47.0   0.1340
  **Current CD4+ T lymphocyte count**                                                                                                                                                                                                                                                
                                                            \< 200 cells/mm^3^                  15                                      8.4          6                       16.7         0.5635                                    2              10.5         0.9222   4    23.5   0.3957
                                                            200 and 350 cells/mm^3^             32                                      18.0         8                       22.2         0.7873                                    5              26.3         0.6634   3    17.6   0.9863
                                                            \> 350 cells/mm^3^                  131                                     73.6         22                      61.1         0.2136                                    12             63.2         0.4401   10   58.9   0.3021
  **Current viral load**                                                                                                                                                                                                                                                             
                                                            \< minimum limit copies/ml          104                                     58.4         11                      30.6         0.0848                                    6              31.6         0.2001   5    29.4   0.2039
                                                            Minimum limit - 100,000 copies/mL   69                                      38.8         22                      61.1         0.0726                                    11             57.9         0.2360   11   64.7   0.1134
                                                            \> 100,000 copies/mL                5                                       2.8          3                       8.3          0.7502                                    2              10.5         0.6904   1    5.9    0.8637

VVC, vulvovaginal candidiasis;

*p* \< 0.05 was considered significant.

The HIV infected group showed a higher frequency of colonization than VVC (52.8% and 47.2%, respectively, *p* = 0.05), and the control group showed more frequent VVC than colonization (55.5% and 44.4%, respectively; *p* = 0.01). However, comparing the two groups, *Candida* spp. total vaginal isolation was more frequent in the HIV group (n = 36/178, 20.2%) than in the control group (18/200, 9.0%; *p* = 0.003). For clinical conditions, the HIV group showed a similar frequency of vaginal colonization (19/178, 10.7%) (OR = 2.9; 95% CI 0.91-9.6; *p* = 0.1072) and VVC (17/178, 9.5%) (OR = 1.879; 95% CI 0.8657-1.994; *p* = 0.4057) to the control group (n = 8/200, 4.0%; n = 10/200, 5.0%, respectively) ([Table 2](#t02){ref-type="table"}).

###### Frequencies of *Candida* spp. vaginal total isolation, colonization and vulvovaginal candidiasis (VVC) in HIV-infected and uninfected women in southern Brazil

                            HIV-infected group   HIV-uninfected group                                                        
  ------------------------- -------------------- ---------------------- ---- ------ ---- ------ ---- ------- --- ------ ---- ------
  *C. albicans*             26                   72.2                   10   52.6   16   94.1   10   55.6    4   50.0   6    60.0
  Non- *albicans* species   10                   27.8                   9    47.4   1    5.9    8    44.4    4   50.0   4    40.0
  Total                     36                   100.0                  19   52.7   17   47.3   18   100.0   8   44.4   10   55.5

With respect to yeast species in the present study, *C. albicans* was the most frequently isolated in both the HIV (n = 26, 72.2%; *p* = 0.02) and control groups (n = 10, 55.6%; *p* = 0.05). With respect to yeast species in different clinical conditions, the HIV group showed more *C. albicans* than the control in VVC (*p* = 0.007; OR 3.1; 95% CI 1.24-9.05) and in colonization (*p* = 0.005; OR 2.9; 95% CI 0.91-10.87). In the HIV group, the following non-*albicans* species were identified: *C. glabrata* (n = 7), *C. parapsilosis* (n = 2) and *C. rugosa* (n = 1). In the control group, the following were identified: *C. glabrata* (n = 5), *C. parapsilosis* (n = 2) and *C. tropicalis* (n = 1). Thus, in both groups, *C. glabrata* was the second most common yeast isolated (19.4% and 27.8%, for the HIV and control groups, respectively) ([Table 2](#t02){ref-type="table"}).

[Table 3](#t03){ref-type="table"} shows the interpretation of the antifungal activity results for drugs as well as for susceptibility, dose-dependent susceptibility or resistance. In general, the *C. albicans* isolates showed no resistance to the antifungal agents tested for both the HIV and the control group. The results for amphotericin B were 100% sensitivity. For nystatin, the results showed elevated rates of vaginal isolates of *C. albicans* and non-*albicans* species with dose-dependent susceptibility. Of the non-*albicans* species identified in the HIV group, only *C. glabrata* showed resistance, one (4.8%) to FLU, two (9.5%) to ITRA, and another two (9.5%) to AMB. In the control group, two non-*albicans* yeasts (23.3%) showed resistance to FLU and one (6.7%) to ITRA; the two resistant species found in this group were *C. glabrata* and *C. tropicalis.*

###### Interpretation of the results for minimal inhibitory concentration (MIC) for antifungal drugs in vaginal yeasts from HIV-infected (n = 36, *C. albicans* = 26) and HIV-uninfected groups (n = 18, *C. albicans* = 10)

  Antifungals   HIV-infected group   HIV-uninfected group                                                                                                                          
  ------------- -------------------- ---------------------- ---- ----- ---- ---- --- ------ ---- ------ ---- ----- ---- ------- ---- ------ ---- ---- --- ------- ---- ------ ---- ------
  FLU           24                   92.3                   2    7.7   \-   \-   4   71.4   5    23.8   1    4.8   10   100.0   \-   \-     \-   \-   1   33.3    5    43.4   2    23.3
  ITRA          25                   96.1                   1    3.9   \-   \-   8   90.5   \-   \-     2    9.5   9    90.0    1    10.0   \-   \-       \-      7    93.3   1    6.7
  NYST          25                   96.1                   1    3.9   \-   \-   8   66.7   2    33.3   \-   \-    3    30.0    7    70.0   \-   \-   6   76.7    2    23.3   \-   \-
  AMB           26                   100.0                  \-   \-    \-   \-   8   90.5   \-   \-     2    9.5   10   100.0   \-   \-     \-   \-   8   100.0   \-   \-     \-   \-

FLU = fluconazole; ITRA = itraconazole; NYST = nistatyn and AMB = amphotericn B; S (susceptible): isolates with MICs ≤ 8 µg/mL for FLU; ≤ 0.125 µg/mL for ITRA; ≤ 4 µg/mL for NYST; ≤ 1 µg/mL for AMB. DDS (dose-dependent susceptibility): isolates with MIC between 16 and 32 µg/mL for FLU; ≤ 0.25 to 0.5 µg/mL for ITRA; ≤ 8 to 32 µg/mL for NYST R (resistant): Isolates with MIC ≥ 64 µg/mL for FLU; ≥1 µg/mL for ITRA; ≥ 64 µg/mL for NYST; ≥ 2 µg/mL for AMB.

DISCUSSION
==========

In the present study, *Candida* spp. total vaginal isolation was significantly more frequent in the HIV group than in the control group. However, a similar frequency of colonization and VVC in the HIV and control groups was shown, which is consistent with the results of the most HIV-infected women enrolled in this study that showed excellent control of the infection. Further, the data regarding HIV infection were not associated with *Candida* spp. isolation from the vaginal mucosa, colonization or VVC.

The results found in this study differ from those described in other populations that also had good control of HIV infection. In these studies, the frequency of VVC in the HIV group was similar to the control group, but the frequency of colonization was higher[@B07] ^,^ [@B15]. Also, for vaginal *Candida* colonization, the results differ from those in which the risk of colonization in HIV-infected women with CD4^+^ T-cell counts below 100-200 cells/mm^3^ was three or four times higher, compared to immunocompetent HIV-infected or HIV-uninfected women[@B01] ^,^ [@B07].

The results are encouraging, since HAART seems to protect against vaginal colonization and VVC, and some investigators have reported a relationship between vaginal *Candida* colonization and VVC with heterosexual transmission of HIV. Recent research has shown that women with vaginal yeasts were more likely to acquire HIV, and the condition may contribute more to the HIV epidemic than previously thought[@B27]. It was shown that treatment of VVC in HIV-infected women can reduce genital shedding of HIV RNA and DNA by 3.2 and 3 times, respectively[@B17].

For the HIV and control groups, *C. glabrata* was the second most common yeast isolated, in agreement with other studies[@B01] ^,^ [@B15]. Older studies described higher rates of vaginal colonization with non-*albicans* species in HIV-infected than in uninfected women[@B07] ^,^ [@B17]. With respect to yeast species in different clinical conditions, the HIV group showed more *C. albicans* than the control group in VVC and in colonization, similar to other studies[@B01]. In some studies, *C. albicans* was related to symptoms in HIV-infected women[@B22], but in others no relationship between symptoms and the yeast species isolated[@B15] was found.

In relation to antifungal susceptibility, *C. albicans* showed no resistance to the antifungal agents tested for both the HIV and the control group and 100% of sensibility for amphotericin B. These results reinforce previous findings showing that amphotericin B is an excellent and highly efficacious therapeutic option for vaginal *C. albicans* including in HIV-infected women[@B08]. For nystatin, the results of this study are in accordance with others that have shown elevated rates of vaginal isolates with dose-dependent susceptibility, and also some resistance[@B05]. Nystatin has been used for several decades as one of the principal treatments for vaginal *Candida* spp. in Brazil[@B23]. This history may partly explain the elevated dose-dependent susceptibility rate observed in both groups studied. Large-scale use of fluconazole began more recently, which may also partly explain the better therapeutic activity of this drug against *C. albicans* found in the present study.

Non-*albicans* species showed resistance to fluconazole and itraconazole. In general, these results are not surprising since the management of women with non-*albicans* species, mainly *C. glabrata,* is difficult because of the lower sensitivity of non-*albicans* species to both azoles[@B06] ^,^ [@B25] and polyenes[@B10]. To the authors\' knowledge, this is one of the first studies to show amphotericin B resistance in *C. glabrata* isolated from HIV-infected women. The importance of the results in relation to antifungal susceptibility is confirmed by the report which found no trials that addressed treatment of VVC in HIV-infected women[@B20]. However, there is a need to evaluate drugs and drug regimens for VVC treatment and prophylaxis in HIV-infected women.

In conclusion, this study found higher frequencies of total vaginal *Candida* spp. isolation in the HIV-infected women with prolonged HAART use, in relation to HIV-uninfected. However, a similar frequency of colonization and VVC in the HIV and control groups was shown. Thus, the results are encouraging, since HAART seems to protect against vaginal colonization and VVC. Although *C. albicans* was the most frequent and sensitive to azolics and polyenes in both HIV-infected and uninfected women, the emerging resistance of *C. glabrata* to amphotericin B in the HIV-infected women studied was observed. If this proves to be correct, implementing routine culture identifications of vaginal *Candida* spp. in HIV-infected women could help in guiding treatment, assisting in care, and improving the quality of life of these patients. Once the resistance of *C. glabrata* to amphotericin B is detected, and this yeast is intrinsically resistant to azoles, it is important to have knowledge of their involvement in VVC of HIV-positive women.
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